Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

  On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab product for adult patients..

Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS

  On January 21, 2025, the Food and Drug Administration sanctioned treosulfan (Grafapex, medac GmbH), an alkylating agent, in conjunction with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell tra..

Latest therapies in the treatment of hematological malignancies

  Introduction Hematological malignancies, such as leukemias, lymphomas, and multiple myeloma, are a heterogeneous group of cancers that arise in the bone marrow and lymphatic system. Conventional treatments like chemothera..

CAR T Cell Therapy for Blood Cancers

  Introduction Blood cancers, also known as hematologic malignancies, include leukemia, lymphoma, and multiple myeloma. These cancers have their origins in either bone marrow or the lymphatic system and are characterized by..

CAR T-Cell therapy for lymphoma

Introduction CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional therapies. This has been quite successful in targeting cancer cells within..

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignant B cells in the blood, bone m..

Abecma, BCMA

Understanding BCMA: A Revolutionary Target in Cancer Treatment

Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted repercussions. One such intri..

BALL, Philadelphia chromosome

Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination with chemotherapy in adult patients who have recently been diagnosed with..

ALL, Besponsa, Leukemia, Merck

Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia

6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) ..

The Life-Changing Treatment for Blood Cancer Finally Exposed!

Blood cancer is a type of cancer that affects both the blood and bone marrow. It is the fifth most common type of cancer in the world, with around 1.24 million new cases diagnosed each year. Wondering is blood cancer curable? Fin..